Tezamorelin vs Szermorelin: Ket GHRH Analog Osszehasonlitasa
Szerkesztőbizottság
Kutatási részleg
Ez a lokalizált összefoglaló bizonyítékokra épülve mutatja be ezt a témát. A teljes tartalom szerkesztőségi egység miatt angol nyelven marad.
Tesamorelin vs Sermorelin: GHRH Analog Comparison
Tesamorelin and sermorelin both operate through GHRH receptor signaling, but they are used in different research contexts. Sermorelin is typically used as a classic active-fragment GHRH analog for axis-signaling studies; tesamorelin is often discussed in endocrine-metabolic crossover settings, especially where visceral adiposity endpoints are relevant.
Side-by-Side
| Property | Tesamorelin | Sermorelin |
|---|---|---|
| Class | Stabilized GHRH analog (N-terminal modification) | GHRH(1-29) analog |
| Primary Pathway | GHRH receptor | GHRH receptor |
| Molecular Size | 44 amino acids | 29 amino acids |
| Common Research Focus | Endocrine-metabolic, visceral adipose tissue | GH-axis signaling, comparator protocols |
| Comparator Position | Endpoint-driven GHRH analog | Baseline/reference GHRH analog |
Same Receptor Class, Different Study Intent
Both compounds engage the GHRH receptor, so the meaningful differences in research design are less about receptor identity and more about intended endpoints and the molecular stability profile each compound provides.
Tesamorelin's N-terminal modification increases metabolic stability compared to native GHRH fragments, which matters for translational studies where consistent exposure is a design requirement. Sermorelin, as the classic GHRH(1-29) analog, functions well as a reference compound when characterizing pathway behavior is the primary objective.
How to Choose Between Them
- Mechanism-first, axis-focused research → sermorelin is a cleaner baseline analog.
- Endpoint-first research with visceral adiposity or metabolic readouts → tesamorelin may be a better fit for comparator framing.
In both cases, timing and duration strongly influence interpretation. See the ipamorelin vs sermorelin comparison for how GHRH-pathway compounds contrast with GHSR-pathway compounds.
Bottom Line
Tesamorelin and sermorelin target the same receptor, but the typical research questions they are used to answer are different. Let endpoint — not branding — drive selection.
Educational content only. Not medical advice.
Bizonyítékok és hivatkozások
Szakértői referenciák a cikkben szereplő kapcsolódó peptidekhez. Így könnyebb ellenőrizni, összevetni és idézni.
Tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation
Tesamorelin • Falutz J, et al. • N Engl J Med (2007)
DOI: 10.1056/NEJMoa071175Sermorelin: a growth hormone-releasing hormone analog
Sermorelin • Thorner MO, et al. • J Clin Endocrinol Metab (1993)
DOI: 10.1210/jcem.77.5.8077320Ipamorelin, the first selective growth hormone secretagogue
Ipamorelin • Raun K, et al. • Eur J Endocrinol (1998)
DOI: 10.1530/eje.0.1390552Böngészés a könyvtárban
GYIK — válaszok előre
Rövid kérdések és válaszok az olvashatóság és a keresőrendszerek számára.
Do tesamorelin and sermorelin work through different receptors?
No. Both are GHRH-pathway compounds targeting the GHRH receptor. The main differences are molecular design (stability, length) and the typical endpoints emphasized in research protocols.
Which is better for pure GH-axis comparator studies?
Sermorelin is commonly chosen as the simpler baseline comparator in axis-focused designs. Tesamorelin is more often used when metabolic endpoint framing (such as visceral adiposity) is important.
További témák
Kutatási minőségű peptidek harmadik fél általi teszteléssel és analitikai bizonyítvánnyal.
Shop Peptides